COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00226447
Recruitment Status : Completed
First Posted : September 27, 2005
Last Update Posted : October 24, 2008
Hoffmann-La Roche
Information provided by:
Chinese University of Hong Kong

Brief Summary:
The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: Pegylated Interferon Drug: Lamivudine Phase 2

Detailed Description:

Chronic hepatitis B is a major cause of mortality and morbidity in Hong Kong and most Southeast Asian countries. The efficacy interferon-alfa (IFN-alfa) or lamivudine monotherapy is far from satisfactory with approximately 20% sustained viral response. Extended use of lamivudine is associated with the emergence of drug resistance mutants. As interferon is an immune modulator and lamivudine directly suppresses viral replication, it is therefore logical to combine the 2 drugs for more efficient viral clearance.

Previous studies on IFN-alfa and lamivudine combination treatment of chronic hepatitis B showed marginal benefit over lamivudine monotherapy. In these studies, lamivudine was either started 8 weeks prior to IFN-alfa or simultaneous with IFN-alfa. Recently, we have performed a study comparing the efficacy of polyethylene glycol-interferon alfa-2b (PEG-Intron A) and lamivudine versus lamivudine monotherapy for 1 year in the treatment of chronic hepatitis B. In our protocol, PEG-Intron A is started 8 weeks before the commencement of lamivudine, and PEG-Intron A is given for 32 weeks while lamivudine is given for a total of 52 weeks. Our published results suggested PEG-Intron A and lamivudine combination treatment is far superior to lamivudine monotherapy (end of treatment virological response 92% vs 20%, p=0.0015). We are not certain whether the benefit of PEG-Intron A and lamivudine combination in our study is due to our staggered regime, the superiority of PEG-Intron A over IFN-alfa, or both. The aim of this study is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B
Study Start Date : December 2002
Actual Primary Completion Date : July 2006
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. HBV DNA reduction at week 52

Secondary Outcome Measures :
  1. Normalization of ALT & negative HBV DNA at EOT, negative HBV DNA at EOT & 24 weeks after cessation of treatment, normalization of ALT at the end of treatment and 24 weeks after the cessation of treatment, Safety of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HBsAg positive for at least 6 months prior to screening
  • Serum HBV-DNA > 10^6 copies per ml at screening
  • Serum HBeAg positive at screening
  • Abnormal ALT (1.3-10x upper limit normal) within one month prior to entry
  • Compensated liver disease with the following minimum criteria:

    1. Hemoglobin within range & not less than 10% from lower normal limit
    2. WBC >= 4,000/mm3
    3. Platelets >= 100,000/mm3
    4. Bilirubin normal (except for Gilbert's disease).
    5. Albumin stable and normal
  • Serum creatinine normal or not more than 10% above the upper normal limit
  • Thyroid Stimulating Hormone (TSH) within normal limits (Patients requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met.)
  • Alfa-fetoprotein in normal range (obtained within the previous year, or if elevated and < 500 ng/ml with a negative ultrasound for hepatocellular carcinoma at screening).
  • Written informed consent

Exclusion Criteria:

  • Co-infection with hepatitis C virus and/or HIV
  • Evidence or history of decompensated liver disease

    1. Child's B cirrhosis
    2. Ascites, bleeding varices, spontaneous encephalopathy
    3. Hypersplenism (hemoglobin, white cell count, platelet outside inclusion criteria)
    4. Coagulopathy (PT > 13 sec)
  • Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the treatment such as:
  • Pre-existing psychiatric condition, especially severe depression, or a history of severe psychiatric disorder.
  • Patients on anti-depressant therapy are excluded
  • CNS trauma or active seizure disorders requiring medication
  • Poorly controlled diabetes mellitus
  • Immunologically mediated disease (e.g., inflammatory bowel disease (Crohn's disease, ulcerative colitis, idiopathic thrombocytopenic purpura, lupus erythematous, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).
  • Clinical gout
  • ANA > 1:320
  • documentation that women of childbearing potential are using contraception. A serum pregnancy test obtained within two weeks prior to initiation of treatment must be negative. Female patients must not be breast feeding.
  • Any known history of hypersensitivity to nucleoside analogues or interferon
  • Previous use of interferon, lamivudine, immunosuppressive drugs or corticosteroid
  • Subjects with clinically significant retinal abnormality
  • Substance abuse, such as alcohol (>80 g/day), iv drugs and inhaled drugs. If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 years. Subjects receiving methadone within the past 2 years are also excluded.
  • Subjects not willing to be counseled/abstain from the consumption of alcohol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00226447

Layout table for location information
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong SAR, China
Sponsors and Collaborators
Chinese University of Hong Kong
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Henry LY Chan, MD Chinese University of Hong Kong

Layout table for additonal information
Responsible Party: Professor LY Chan, Chinese University of Hong Kong Identifier: NCT00226447    
Other Study ID Numbers: P03227
First Posted: September 27, 2005    Key Record Dates
Last Update Posted: October 24, 2008
Last Verified: October 2008
Keywords provided by Chinese University of Hong Kong:
Chronic Hepatitis B
Pegylated Interferon
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents